Interactions among Hageman factor, plasma prekallikrein, high molecular weight kininogen, and plasma thromboplastin antecedent.
To investigate the earliest steps of the intrinsic clotting pathway, Hageman factor (Factor XII) was exposed to Sephadex gels to which ellagic acid had been adsorbed; Hageman factor was then separated from the gels and studied in the fluid phase. Sephadex-ellagic acid-exposed Hageman factor, whether purified or in plasma, activated plasma thromboplastin antecedent, but only when high molecular weight kininogen was presnet. In the absence of plasma prekallikrein, maximal activation of plasma thromboplastin antecedent was slightly delayed in plasma, a delay not observed with similarly treated purified Hageman factor. Thus, high molecular weight kininogen was needed for expression of Hageman factor's clot-promoting properties and plasma prekallikrein played a minor role in the interaction of ellagic acid-treated Hageman factor and plasma thromboplastin antecedent.
D001777:Blood Coagulation / Q000187:drug effects; D004610:Ellagic Acid / Q000494:pharmacology; D005172:Factor XI / Q000378:metabolism*; D005174:Factor XII / Q000378:metabolism*; D006801:Humans; D007610:Kallikreins / Q000378:metabolism*; D007704:Kininogens / Q000378:metabolism*; D008970:Molecular Weight; D011288:Prekallikrein / Q000378:metabolism*
D007704:Kininogens; D004610:Ellagic Acid; D005174:Factor XII; D005172:Factor XI; D011288:Prekallikrein; D007610:Kallikreins